Delmira: A Peptide-Based Approach to Overcoming Leptin Resistance

This report examines Delmira, a novel peptide designed to combat leptin resistance and facilitate weight loss. Delmira, derived from the Greek word for protector, aims to sensitize impaired leptin receptors, addressing a key issue in obesity. The peptide acts by restoring leptin receptor action through STAT3 phosphorylation, controlling leptin release, and mitigating ER stress-induced inflammation. By targeting the production of leptin in adipocytes and overcoming inhibitions faced by leptin receptors in obese individuals, Delmira aims to increase energy expenditure and reduce food intake. The report references studies on leptin's effects on immune cells and its role in reducing food intake and increasing energy expenditure. This student contributed assignment is available on Desklib, where you can find more solved assignments and past papers.

DELMIRA- WEAPON TO WEIGHT LOSS
Salient Features of Delmira
• Restores Leptin receptor action
• Sensitizes LepR
• Controls release of Leptin
• Checks ER stress
• Helps to restore immune action
• Removes macrophage blockage
• Stimulate release of effector T
cells
References
LEPTIN-Made by
adipose cells and released
primarily as a hormone
• The receptor is LepR that acts
through STAT3
• Downstream phosphorylation
of STAT3 causes proliferation,
induction of apoptosis along
with induction of
inflammation (Reis et
al.,2015)
• Inhibition of Leptin
interaction causes blockage of
phagocytic actions as well as
maturation of dendritic cells
as studies show that Leptin
has effect on a range of
immune cells such as
macrophages, T cells , Bcells
or NK cella
• Leptin has been treated on
animal model and the results
in Leptin-deficient mice
reveals that there is deficiency
in T- cell development in the
thymus. There was decrease in
the responses of effector T
cells (Reis et al.,2015)
b) Leptin reduces food intake,
increases energy expenditure and
reduces body weight by reducing
expression of MCH and orexins in
the LCA area(Park & Ahima,2014)
Delmira is derived from a Greek
word meaning the protector
The new theoretical drug will
interfere with the adipocytes as the
origin of Leptin is from the white
cells of adipose tissue so the new
drug will act on the production of
Leptin.
As the name suggests the drug will
help in overcoming the inhibitions
faced by the receptors of Leptin by
the obese people (Erhuld et
al.,2013).
Peptide Pathway
Protein Name
Signaling Cascade
Fig 1: Wnt signaling cascade in lean and obese people
Pharmacological Action
However, Leptin therapy is much more
useful in people with a single gene
mutation and not with people who are
obese (Roujeau, Jockers & Dam,2014).
Thus, Leptin action can be restored by the
addition of Delmira that will act on the
production of Leptin.
High ER stress induces Leptin resistance
(Quarta et al.,2016) and thus the
sensitization of impaired Leptin
receptor (Roujeau, Jockers &
Dam,2014)
Receptor activation and action of Leptin
through the drug Delmira (Meyers,2015). This
will cause the drug to work at the receptor of
Leptin that will help to restore the action of
Leptin and thus increase the energy
expenditure and reduce food intake.
Ehrlund, A., Mejhert, N., Lorente-Cebrián, S., Åström, G., Dahlman, I., Laurencikiene, J., &
Rydén, M. (2013). Characterization of the Wnt inhibitors secreted frizzled-related proteins
(SFRPs) in human adipose tissue. The Journal of Clinical Endocrinology &
Metabolism, 98(3), E503-E508.
Myers Jr, M. G. (2015). Leptin keeps working, even in obesity. Cell metabolism, 21(6), 791-
792.
Park, H. K., & Ahima, R. S. (2014). Leptin signaling. F1000prime reports, 6, 73.
doi:10.12703/P6-73
Quarta, C., Sánchez-Garrido, M. A., Tschöp, M. H., & Clemmensen, C. (2016). Renaissance
of leptin for obesity therapy. Diabetologia, 59(5), 920-927.
Reis, B. S., Lee, K., Fanok, M. H., Mascaraque, C., Amoury, M., Cohn, L. B., ... & Mucida, D.
(2015). Leptin receptor signaling in T cells is required for Th17 differentiation. The Journal of
Immunology, 194(11), 5253-5260.
Roujeau, C., Jockers, R., & Dam, J. (2014). New pharmacological perspectives for the leptin
receptor in the treatment of obesity. Frontiers in endocrinology, 5, 167.